Loading clinical trials...
Loading clinical trials...
Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
Age
All ages
Sex
FEMALE
Healthy Volunteers
No
Numakunai, Iwate, Japan
Aichi, Japan
Akita, Japan
Chiba, Japan
Fukui, Japan
Fukuoka, Japan
Fukushima, Japan
Gifu, Japan
Gunma, Japan
Hiroshima, Japan
Start Date
October 1, 2015
Primary Completion Date
March 31, 2018
Completion Date
March 31, 2018
Last Updated
October 21, 2024
793
ACTUAL participants
Ramosetron
DRUG
Lead Sponsor
Astellas Pharma Inc
NCT06737666
NCT05369884
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions